RemeGen Co., Ltd. filed its Monthly Return with the Hong Kong Stock Exchange for the period ended 31 May 2026, confirming no changes to either its H-share or A-share counts during the month.

• Share Capital Structure – Authorised/registered share capital remained at 564.48 million shares with a par value of RMB 1 each. – H-shares in Hong Kong: 208.58 million issued shares; no treasury shares; zero movement versus April 2026. – A-shares in Shanghai: 355.70 million issued shares and 0.19 million treasury shares; no movement during the month.

• Public Float Status RemeGen confirmed compliance with the 5 % minimum public-float threshold applicable to PRC issuers with H-shares.

• Equity Incentive Schemes Outstanding restricted shares that may still be issued under existing plans total 2.18 million A-shares: 1) 2022 A Share Incentive Scheme – First Grant: 0.74 million shares remaining. 2) 2022 A Share Incentive Scheme – Reserved Grant: 0.36 million shares remaining. 3) 2023 A Share Incentive Scheme – First Grant: 1.08 million shares remaining.

• Capital Instruments The company reported no share options, warrants, convertibles, or other agreements that affected issued share capital in May 2026.

The filing was signed by Director Wang Weidong on 4 June 2026.